Overview

Docetaxel, Estramustine, and Thalidomide in Treating Patients With Androgen-Independent Metastatic Adenocarcinoma of the Prostate

Status:
Completed

Trial end date:
2007-12-01

Target enrollment:

Participant gender:

Summary

RATIONALE: Drugs used in chemotherapy, such as docetaxel and estramustine, work in different ways to stop tumor cells from dividing so they stop growing or die. Thalidomide may stop the growth of prostate cancer by stopping blood flow to the tumor. Giving chemotherapy together with thalidomide may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving docetaxel and estramustine together with thalidomide works in treating patients with androgen-independent metastatic adenocarcinoma (cancer) of the prostate.

Phase:

Phase 2

Details

Lead Sponsor:

National Institutes of Health Clinical Center (CC)

Collaborator:

National Cancer Institute (NCI)

Treatments:

Androgens
Docetaxel
Estramustine
Thalidomide